TUSTIN, Calif., Oct. 22 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. AMDL announced today that its management will present on November 7, 2007, at the prestigious 9th Annual Healthcare Conference sponsored by the full-service investment bank, Rodman & Renshaw, and its life science division, Acumen BioFin(TM). The presentation will be at 2:40 PM in the Kennedy I Room (4th floor).
"The Rodman & Renshaw conference, which annually presents more than 350 companies to institutional investors, venture capitalists, and sophisticated private investors, is a major opportunity for AMDL to tell the story of its pharmaceutical successes in China," said Gary Dreher, CEO. Companies at the conference specialize in cardiovascular diseases, drug delivery, gene therapy and oncology, among other areas of investigation.
The conference is November 5 - 7 at the New York Palace Hotel, 450 Madison Avenue, New York. Information about the conference is available at Conference Schedule: http://www.rodmanandrenshaw.com/us07conference under "Program."
About JPI: Jade Pharmaceutical has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injectable fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
|SOURCE AMDL, Inc.|
Copyright©2007 PR Newswire.
All rights reserved